🔎 Trials Near Me

Home › Blood Cancers › California › Orange

Blood Cancers clinical trials in Orange, CA

7 studies for Blood Cancers are looking for participants at sites in and around Orange (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

RecruitingPhase 3
  • University of California, Irvine, Orange
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RecruitingPhase 1
  • UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT06001788

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RecruitingObservational study
  • Children's Hospital of Orange County (CHOC), Orange
All ages · All sexes · Updated Jul 6, 2026 · NCT01351545

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RecruitingPhase 1
  • UC Irvine Health Chao Family Comprehensive Cancer Center, Orange
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

RecruitingPhase 2
  • Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
Ages 18 to 70 · All sexes · Updated Feb 2, 2026 · NCT06028828

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

RecruitingPhase 1
  • Children's Hospital Orange County, Orange
Ages 1 to 21 · All sexes · Updated Dec 6, 2024 · NCT05476770

Blood Cancers trials in other cities

Other studies in Orange

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.